Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"" to "<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"") |
Warner-admin (talk | contribs) m (Text replacement - "=Guidelines=" to "=Guidelines= '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''") |
||
Line 12: | Line 12: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf NCCN Guidelines - Kidney Cancer].'' | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf NCCN Guidelines - Kidney Cancer].'' |
Revision as of 18:57, 17 October 2023
Page editor | Section editor | ||
---|---|---|---|
Teja Ganta, MD Icahn School of Medicine at Mount Sinai New York, NY, USA |
Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA |
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
All lines of therapy
Belzutifan monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Jonasch et al. 2021 (MK-6482-004) | 2018-05-31 to 2019-03-29 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03401788